Thymic epithelial tumors including thymomas and thymic carcinomas are relatively rare diseases and have a variety of histology because there are a variety of tissues and organs around the thymus. Therefore, appropriate treatments should be selected according to the respective histology. However, the standard care for advanced thymoma and thymic carcinoma has not yet been established because there have been no large randomized trials due to the rarity of the diseases and the poor prognosis. In the advanced setting, chemotherapy has been a mainstay using platinumbased chemotherapy such as ADOC, CAP, VIP, PE, carboplatin/paclitaxel. In second-line or later of chemotherapy, chemotherapeutic regimens have also not been established. In this situation, S-1 (an oral fluorouracil) appears to be active in patients with thymic carcinomas. Some cases using molecular target agents, such as histone deacetylase inhibitors for thymoma, sunitinib for thymic carcinoma have been reported; however, molecular biological approaches are still under investigation.
|Number of pages||12|
|Journal||Japanese Journal of Chest Diseases|
|Publication status||Published - 2013|
- Thymic carcinoma
- Thymic epithelial tumor
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine